Abstract
Simple SummaryCurrently, the therapeutic arsenal to fight cancers is extensive. Among these, antibody–drug conjugates (ADCs) consist in an antibody linked to a cytotoxic agent, allowing a specific delivery to tumor cells. ADCs are an emerging class of therapeutics, with twelve FDA- and EMA-approved drugs for hematological and solid cancers. In recent years, tremendous progress has been observed in therapeutic approaches for advanced skin cancer patients. ADCs appear as an emerging therapeutic option in oncodermatology. After providing an overview of ADC design and development, the goal of this article is to review the potential ADC indications in the field of oncodermatology.Antibody–drug conjugates (ADCs) are an emerging class of therapeutics, with twelve FDA- and EMA-approved drugs for hematological and solid cancers. Such drugs consist in a monoclonal antibody linked to a cytotoxic agent, allowing a specific cytotoxicity to tumor cells. In recent years, tremendous progress has been observed in therapeutic approaches for advanced skin cancer patients. In this regard, targeted therapies (e.g., kinase inhibitors) or immune checkpoint-blocking antibodies outperformed conventional chemotherapy, with proven benefit to survival. Nevertheless, primary and acquired resistances as well as adverse events remain limitations of these therapies. Therefore, ADCs appear as an emerging therapeutic option in oncodermatology. After providing an overview of ADC design and development, the goal of this article is to review the potential ADC indications in the field of oncodermatology.
Highlights
In 1909, the German chemist Paul Ehrlich [1] provided the first description of “targeted therapy”
Since patients treated with brentuximab vedotin do not achieve improvements in long-term outcomes, new Cutaneous T-cell lymphoma (CTCL) targets were identified and new antibody–drug conjugates (ADCs) were developed
PD-1 inhibitors are currently recommended as first-line treatment of advanced squamous cell carcinoma (SCC) which are not candidates for surgery or radiation therapy [96]
Summary
In 1909, the German chemist Paul Ehrlich [1] provided the first description of “targeted therapy” He proposed the so called “magic bullet” concept, allowing the delivery of a therapeutic molecule to a specific target without affecting healthy tissues [2]. Targeted therapies are used in daily oncology practice including oncodermatology. Antibody–drug conjugates (ADCs) combine a monoclonal antibody (mAb) with a highly cytotoxic molecule, allowing its specific delivery to tumor cells [4]. Optimization of ADC technologies in order to increase their therapeutic performances and overcome their limitations as well as evaluation of their effects in combination with currently approved drugs have significantly expanded their use in oncology [5,6]. The following parts aim to provide a brief overview of the features of the different ADC components and how these can impact efficacy and safety
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
